Iovance Biotherapeutics Azioni (NASDAQ: IOVA)

Ultime notizie per Iovance Biotherapeutics (NASDAQ:IOVA) Azioni

IOVANCE BIOTHERAPEUTICS INC

Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Northeastern States Rank High

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ARVN

IOVA

Analizziamo le aziende con RSI basso, che potrebbero offrire interessanti opportunità di profitto nel mercato finanziario. Ecco i nomi.

3 titoli del settore sanitario destinati a decollare nel prossimo trimestre

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics Inc

RVYL

Ryvyl Inc. Secures Major Payments-as-a-service Contracts, Onboards 10,000+ Accounts In First Month

Earnings

Earnings Beats

CGNT

Cognyte Software Q4 2025 Adj. EPS $0.03 Beats $0.01 Estimate, Sales $94.505M Beat $93.154M Estimate

HC Wainwright &amp; Co. analyst Edward White reiterates Valneva (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>) with a Buy and maintains $17 price target.

Price Target

Reiteration

Analyst Ratings

VALN

HC Wainwright & Co. Reiterates Buy on Valneva, Maintains $17 Price Target

AMC Entertainment Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) and IMAX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) have entered into a major agreement that will introduce IMAX with Laser technology to over 180 AMC and IMAX locations across the country.
As part of this deal, AMC will add 12 new IMAX locations and upgrade 68 existing ones to the IMAX with Laser format.
This expansion will create the largest IMAX with Laser circuit in the world.
The agreement marks the largest systems agreement IMAX has signed in the U.S. since 2018.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/travel/25/04/44592941/tariff-tensions-could-hurt-us-gdp-as-canadian-tourism-cools-goldman-sachs" rel="noreferrer noopener">Tariff Tensions Could Hurt US GDP As Canadian Tourism Cools: Goldman Sachs</a>
IMAX and AMC have been partners since 2007, and AMC operates eight of the ten highest-earning IMAX theaters in the U.S.
&#8220;Throughout the United States and around the world, filmmakers and moviegoers hold the IMAX brand in such high regard as a premium theatrical spectacle, which is reflected both in the success that AMC and IMAX share together, and in IMAX&#8217;s extensive content catalogue,&#8221; said Chairman and CEO, AMC Entertainment, Adam Aron.
Under its AMC Go Plan, the company continues to prioritize premium moviegoing experiences, featuring advanced visuals, immersive sound, and upgraded seating.
Price Action: AMC shares closed lower by 3.14% at $2.78 on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44589543/ford-trucks-hit-20-year-sales-high-as-ev-demand-climbs" target="_blank" rel="noreferrer noopener">Ford Q1 US Auto Sales Dip 1.3%: Details</a></li>
</ul>
Photo: Shutterstock.

Equities

Contracts

General

IMAX

AMC Expands Premium Movie Experience With IMAX Laser Upgrades In Landmark Deal

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) from Neutral to Neutral.

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

HC Wainwright & Co. Reiterates Neutral on Mawson Infra Grto Neutral

HC Wainwright &amp; Co. analyst Kevin Dede reiterates LM Funding America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMFA#NASDAQ">LMFA</a>) from Neutral to Neutral.

LMFA

HC Wainwright & Co. Reiterates Neutral on LM Funding Americato Neutral

Pintail is headquartered in Midland, Texas and is a provider of oilfield wireline services in the Permian basin.
Acquisition is expected to be accretive to RPC's 2025 earnings per share and operating and free cash flow (operating cash flow less capital expenditures).
Consideration was comprised of a combination of approximately $170 million cash-on-hand, $25 million of RPC restricted stock consideration and a $50 million three-year note to one of the sellers.
&nbsp;

RPC Reveals Acquisition Of Pintail Alternative Energy, Which Does Business Under Name Pintail Completions, For $245M

Parsons Corporation Wins Contract For PFAS Investigation At Tucson International Airport

As part of this collaboration, Zendesk will integrate TELUS Digital's global CXM talent into its support solutions granting immediate access to a global network of 78,000 team members across 31 countries.&nbsp;
In turn, TELUS Digital will incorporate Zendesk's customer relationship management (CRM) and call center as a service (CCaaS) technologies in its suite of offerings.&nbsp;

TIXT

TELUS Digital Enters New Strategic Collaboration With Zendesk

https://www.reuters.com/business/autos-transportation/teslas-china-made-ev-sales-fall-115-yy-march-2025-04-02/#:~:text=BEIJING%2C%20April%202%20(Reuters),(CPCA)%20showed%20on%20Wednesday.

TSLA

Reuters Reported Earlier, China Passenger Car Association Said Tesla Sold 78,828 China-made Electric Vehicles In March, Down 11.5% YoY

Collective Mining Reveals Plans For An Expanded Drill Program Following The Successful Completion Of Its Recent Financing For C$63.4M

Trilogy Metals Reports Q1 Results: Reports Net Loss Of $3.6M, Flat YoY, Exits Quarter With Cash And Equivalents Worth $25.2M

In the lead-up to &#8216;Liberation Day&#8217;, car dealerships in the US are seeing a spike in footfalls, as consumers race to book their new vehicles to avoid the post-tariff sticker shock that, according to some estimates, could <a href="https://benzinga.com/markets/25/03/44556198/tesla-bull-says-there-are-no-winners-with-trumps-auto-tariffs-calls-it-pure-chaos-for-global-supply-chains">reach as high as $10,000 to $15,000</a> even for mid-range cars.
What Happened: The looming 25% tariffs on all car imports to the US is set to become a reality within a few short hours, and it&#8217;s not just on the cars that are imported, but also those that are made in the US, but use imported parts. Since there is no such thing as an &#8216;All-American Car,&#8217; pretty much every make and model will see prices spike in the coming days.
See More: <a href="https://www.benzinga.com/markets/equities/25/04/44578839/trumps-25-tariff-on-imported-vehicles-could-shatter-detroits-auto-economy-warns-business-leaders-it-will-hurt-hardworking-americans">Trump&#8217;s 25% Tariff On Imported Vehicles Could Shatter Detroit&#8217;s Auto Economy, Warns Business Leaders: &#8216;It Will Hurt Hardworking Americans&#8217;</a>
Erin Keating, an analyst at Cox Automotive, said in a note that after this spike, which will last several days, auto sales will crater for the next several months. Both used and new car prices will increase, and certain models will be eliminated from American markets.
Keating further adds, &#8220;We have seen this movie before. During COVID, supply became constrained, costs skyrocketed. While the increase in prices this time may be for completely different reasons, it still stands to reason that the market will not bear another significant increase,&#8221; highlighting the risks these tariffs pose to the auto industry.
Why It Matters: As a result, car makers and dealerships are expected to have a good first quarter, but that&#8217;s not necessarily the case for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), which is set to report its deliveries during the quarter on Wednesday.
Analysts expect the company to report its worst quarterly growth in years with just under 410,000 deliveries, up by a mere 5% from the prior year. This was expected as the brand took a nosedive across several key markets in recent months, in response to Elon Musk&#8217;s increasing political involvement.
Tariffs are set to <a href="https://in.benzinga.com/25/03/44507598/elon-musk-warns-of-significant-impact-on-tesla-due-to-trumps-auto-tariffs-the-cost-impact-is-not-trivial">hurt Tesla especially hard</a> since analysts estimate that they would add as much as $12,000 to the prices of most current EV models.
As you can expect, Tesla isn&#8217;t doing too well with all these issues, and according to Benzinga&#8217;s Edge Rankings, the stock is unfavorable in short, medium, and long-term. To see how the EV giant compares with its peers and competitors, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">check out Benzinga Edge Pro</a>.
<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02061119/Screenshot-2025-04-02-at-3.37.04-PM-1024x168.png" alt="" class="wp-image-852942" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02061119/Screenshot-2025-04-02-at-3.37.04-PM-1024x168.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02061119/Screenshot-2025-04-02-at-3.37.04-PM-300x49.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02061119/Screenshot-2025-04-02-at-3.37.04-PM-768x126.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02061119/Screenshot-2025-04-02-at-3.37.04-PM.png 1418w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44522387/japanese-automakers-face-29-billion-tariff-hit-nissan-mazda-subaru-most-at-risk-says-analyst">Japanese Automakers Face $29 Billion Tariff Hit, Nissan, Mazda, Subaru Most At Risk, Says Analyst</a></li>
</ul>
Photo courtesy: Shutterstock

Government

Tech

US Car Buyers Throng Dealerships As Trump's Tariff Threat Looms Over Prices

Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) will release its second-quarter financial results after the <a href="https://www.benzinga.com/quote/FC/earnings">closing bell on Wednesday, April 2</a>.
Analysts expect the Salt Lake City, Utah-based company to report a quarterly loss at 6 cents per share, versus a year-ago profit of 19 cents per share. Franklin Covey projects quarterly revenue of $62.65 million, compared to $61.34 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 8, Franklin Covey posted downbeat results for the first quarter.
Franklin Covey shares rose 1.4% to close at $28.00 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/FC/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Barrington Research analyst Alexander Paris maintained an Outperform rating with a price target of $45 on March 21, 2025. This analyst has an accuracy rate of 82%.</li>
<li>Roth MKM analyst Jeff Martin reiterated a Buy rating with a price target of $50 on June 27, 2024. This analyst has an accuracy rate of 70%.</li>
</ul>
Considering buying FC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02030522/image-15-1024x580.png" alt="" class="wp-image-852608" style="width:569px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02030522/image-15-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02030522/image-15-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02030522/image-15-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/02030522/image-15.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44584246/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Franklin Covey Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Guidance

Health Care

ANGO

AngioDynamics Expects 2025 Adjusted EPS Loss Of $(0.31)-$(0.34) Compared To Prior Guidance Of $(0.34)-$(0.38) And Consensus Of $(0.37)

Phoenix Motor And InductEV Unveil World-First Wireless Charging For Medium-Duty Electric Shuttle Buses

MBLY

Mobileye Picks Valens' VA7000 MIPI A-PHY Chipsets For Automated And Autonomous Driving Projects

Fiscal Year 2025 Financial Guidance
For fiscal year 2025:
<ul>
<li>The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million.</li>
<li>The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%.</li>
<li>The Company continues to expect Med Device net sales to be flat.</li>
<li>The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%.</li>
<li>The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024. &nbsp;</li>
</ul>
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Guidance Action</td>
<td colspan="1" rowspan="1">
Current Guidance
(As of Apr. 2, 2025)
</td>
<td colspan="1" rowspan="1">
Previous Guidance
(Issued on Jan. 8, 2025)
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Sales</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$285 - $288 million</td>
<td colspan="1" rowspan="1">$282 - $288 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Tech Net Sales Growth</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">14 - 16%</td>
<td colspan="1" rowspan="1">12 - 15%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Med Device Net Sales Growth</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Flat (unchanged)</td>
<td colspan="1" rowspan="1">Flat</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">53 - 54%</td>
<td colspan="1" rowspan="1">52 - 53%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">$4.0 - $5.0 million</td>
<td colspan="1" rowspan="1">$1.0 - $3.0 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">Increased</td>
<td colspan="1" rowspan="1">($0.31) - ($0.34)</td>
<td colspan="1" rowspan="1">($0.34) - ($0.38)</td>
</tr>
</tbody>
</table>
</figure>

AngioDynamics Expects 2025 Net Sales Of $285M-$288M Compared To Prior Guidance Of $282M-$288M And Consensus Of $284.91M

Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.&nbsp;

ENOV

Enovis Appoints Damien McDonald as CEO, Effective May 12 2025, Following Matt Trerotola's Retirement

Michael Quartieri, Chairman of the Company's Board of Directors and Chief Executive Officer, will serve as the Interim Chief Financial Officer until a replacement has been identified and appointed.
Also on March 31, 2025, the Company provided notice of termination to Brandy Treadway, Chief Legal Counsel of the Company, effective as of April 2, 2025
 &nbsp;

Management

RMBL

RumbleOn Provided Notice Of Termination To CFO Tiffany Kice, Effective As Of April 2, 2025 - Filing

Press Releases

Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

Traws Pharma Announces Management Updates

IKNA

TRAW

Ardelyx

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dyne Therapeutics

89bio

Geron

GRAIL

IDEAYA Biosciences

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

MiMedx Group

Mesoblast Limited - American Depositary Shares

Mesoblast

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

MannKind

Novavax

Arcus Biosciences

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Comments

Iovance Biotherapeutics

Notizie

Ultime notizie per Iovance Biotherapeutics (NASDAQ:IOVA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO